Difference between revisions of "MDAI"

From DMT-Nexus Wiki
Jump to: navigation, search
(Brief overview - What is MDAI?)
Line 13: Line 13:
 
== Brief overview - What is MDAI? ==
 
== Brief overview - What is MDAI? ==
  
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA).  Like MDA and MDMA, it produces entactogenic effects.  Unlike similar drugs, it results in little to no stimulant effects.
+
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA).  Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects.

Revision as of 22:17, 19 December 2013

Safety profile Note error.png
Category:
  • Entactogen, Empathogen, SSRA
Main effects:
  • Entactogenic effects, Empathogenic effects, Euphoria
Side effects:
  • Nausea, headache, tiredness, depression, rise in blood pressure
Health risks:
  • Mental addiction
Important safety remarks:
  • Cardiovascular toxicity has not been tested. As of 2013, long-term studies on this substance have not been performed, so long term effects are still UNKNOWN!


Brief overview - What is MDAI?

5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects.